An observational study in Hereditary Angioedema, sponsored by Intellia Therapeutics. Enrolling by invitation at 7 sites in 6 countries. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Intellia Therapeutics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Angioedemas, Hereditary with a site in France — 8 open to participants now, 13 under way, 11 of them phase 3. Angioedemas, Hereditary · France.
Among the 38 studies in Angioedemas, Hereditary with a site in France, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2024, is one of 10 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 26th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →8 of the 38 studies in Angioedemas, Hereditary with a site in France are open now. Recruiting first, the newest first:
ADARx Pharmaceuticals, Inc. · Sites in France, United States, Argentina and 16 more countries
Ages 18+
Pharvaris Netherlands B.V. · Sites in France, United States, Australia and 13 more countries
Ages 18+
ADARx Pharmaceuticals, Inc. · Sites in France, United States, Argentina and 21 more countries
Ages 18+
Astria Therapeutics, Inc. · Sites in France, United States, Brazil and 15 more countries
Ages 12+
Pharvaris Netherlands B.V. · Sites in France, United States, Argentina and 20 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 23 · Phase 4 1
First in 2009; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 43 observational studies indexed under Angioedemas, Hereditary.
Median enrollment 103 across the 28 interventional studies, 194 across the 10 observational. Of the 24 that completed or were terminated, 9 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 38 have an industry lead sponsor. The 10 most frequent:
Intellia Therapeutics is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Intellia Therapeutics has 3 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
5 of the studies in Angioedemas, Hereditary with a site in France that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
| NCT05392114Phase 3Ionis Pharmaceuticals, Inc.A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | 2026-12 |
| NCT05396105Phase 3Pharvaris Netherlands B.V.Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | 2027-06 |
| NCT07266805Phase 3Pharvaris Netherlands B.V.Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | 2027-06 |
| NCT06960213Phase 3ADARx Pharmaceuticals, Inc.STOP-HAE: A Phase 3 Study of ADX-324 in HAE | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Angioedemas, Hereditary with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Participating sites in an Intellia-sponsored clinical study of NTLA-2002.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of treatment-related Adverse Events (AEs); incidence of treatment-related Serious Adverse Events (SAEs); incidence of treatment-related Adverse Events of Special Interest (AESIs) defined per protocol
Time frame: up to 15 years
To evaluate the long-term efficacy of NTLA-2002 in previously treated subjects
Rate of Hereditary Angioedema (HAE) attacks overall and rate of HAE attacks requiring acute therapy. Total plasma kallikrein protein level.
Time frame: up to 15 years
Change from baseline in consumption of on-demand HAE medications for reported HAE attacks
Time frame: up to 15 years
Change from baseline in healthcare utilization for HAE attacks
Time frame: up to 15 years
Change from baseline in QoL parameters as measured by the MOXIE Angioedema-QoL instrument.
Time frame: up to 5 years
Change from baseline in QoL parameters as measured by the EQ-5D-5L instrument.
Time frame: up to 5 years
Change from baseline in QoL parameters as measured by the WPAI:GH instrument.
Time frame: up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Apr 2040, 192 months after the start.
Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's planned 192 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intellia Therapeutics